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S U M M A R Y
Objectives: To describe the clinical features, treatments, outcomes, and subtype prevalence of
cryptococcosis in Singapore.
Methods: All patients with laboratory conﬁrmed cryptococcal infections admitted from 1999 to 2007 to
a teaching hospital in Singapore were reviewed retrospectively. Identiﬁcation and molecular types of
Cryptococcus neoformans variants and Cryptococcus gattii were determined by polymerase chain
reaction–restriction fragment length polymorphism (PCR-RFLP). Serotypes were inferred with a
multiplex PCR method.
Results: Of 62 patients with cryptococcosis, C. neoformans var. grubii was the predominant subtype (in
95%), affecting mainly immunocompromised hosts (91%) with HIV infection (80%). Patients with HIV
were younger (median age 36.5 vs. 49.5 years, p = 0.006) and less likely to present with an altered mental
status (14% vs. 50%, p = 0.013). In contrast, delayed treatment (median 7 days vs. 2 days, p = 0.03),
pulmonary involvement (58% vs. 14%, p = 0.03), and initial treatment with ﬂuconazole (25% vs. 2%,
p = 0.02) were more common in HIV-negative patients. C. gattii was uncommon, affecting only three
patients, all of whom were immunocompetent and had disseminated disease with pulmonary and
neurological involvement. All C. gattii were RFLP type VG II, serotype B and all C. neoformans var. grubii
were RFLP type VN I, serotype A, except for one that was RFLP type VN II.
Conclusion: C. neoformans var. grubii, subtype VN I, was the predominant subtype in Singapore, infecting
younger, mainly immunocompromised hosts with HIV. C. gattii was uncommon, causing pulmonary
manifestations in older, immunocompetent patients and were RFLP type VG II.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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Cryptococcus neoformans is a basidiomycetous encapsulated
yeast with worldwide distribution. After inhalation from environ-
mental sources, this pathogen may result in life-threatening
infections in humans commonly affecting the central nervous
system or respiratory system.1
C. neoformans was previously subclassiﬁed into three varieties
based upon biochemical differences and into four non-hybrid
serotypes according to capsular agglutination reactions:§ Presented as a poster at the 20th European Congress of Clinical Microbiology and
Infectious Diseases (ECCMID), Vienna, Austria, April 10–13, 2010.
* Corresponding author. Tel.: +65 9235 9813; fax: +65 6252 4056.
E-mail addresses: chnmonica@gmail.com, monica_chan@ttsh.com.sg (M. Chan).
http://dx.doi.org/10.1016/j.ijid.2014.05.019
1201-9712/ 2014 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).C. neoformans var. grubii (serotype A), C. neoformans var. neoformans
(serotype D), and C. neoformans var. gattii (serotype B and C).2,3
C. neoformans is the commonest cause of fungal meningitis
worldwide.4,5 C. neoformans var. grubii is an opportunistic
pathogen of immunocompromised patients, with HIV infection,
corticosteroid therapy, haematological malignancies, and solid-
organ transplantation identiﬁed as major risk factors.6,7 Crypto-
coccal meningitis is the fourth most common opportunistic
infection in patients with HIV, with an estimated one million
HIV-associated cryptococcosis cases diagnosed annually world-
wide.5 In Southeast Asia, cryptococcosis is common amongst
HIV-infected individuals, with an estimated 120 cases per 1000
HIV-infected individuals per year.4 The growing size of the
immunocompromised patient population from treatment with
chemotherapy and biological agents will likely further contribute
to the medical importance of cryptococcosis.6ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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C. neoformans due to signiﬁcant differences in genetic, biochemis-
try, ecology, and clinical characteristics.8,9
C. gattii is associated with the unique environmental source of
Australian River and Forest Red Gum trees (Eucalyptus camaldu-
lensis and Eucalyptus tereticornis), although it has also been
cultured from other trees, bird excreta, and soil.9–11 Mainly
restricted to tropical and subtropical regions, a recent large
outbreak of C. gattii in British Columbia and surrounding areas has
highlighted a shift in the geographical distribution.12,13 Unlike
C. neoformans, disease due to C. gattii is usually observed in patients
without signiﬁcant immunosuppression. Characteristics of C. gattii
include a higher rate of brain mass lesions, more refractory
response to antifungal chemotherapy, and more aggressive and
prolonged treatment with increased long-term sequelae and
higher mortality.13–15
In Singapore, identiﬁcation to the species level has only recently
been implemented in clinical laboratories so the historic distribu-
tion of the various serotypes and species is unknown. In addition,
no recent data exist on patient characteristics, treatments, and
outcomes of cryptococcosis since the onset of the HIV epidemic. To
provide this information, our study aimed to describe the
epidemiological, clinical, and outcome aspects of patients with
cryptococcosis admitted to a teaching hospital from 1999 to 2007.
2. Methods
Tan Tock Seng Hospital is a 1400-bed university teaching
hospital in Singapore. We retrospectively reviewed the medical
and microbiological records of all patients aged 16 years or older
hospitalized from March 1999 to June 2007 with cryptococcal
infection. Patient characteristics were extracted from patient
records and included demographic characteristics, co-morbidities,
clinical presentation, radiological and microbiological evaluation
including cerebrospinal ﬂuid (CSF) analysis, antifungal treatment,
adjunctive neurosurgery, and clinical outcomes including length of
hospital stay, hospital re-admission after discharge, and 30-day
mortality.
Cryptococcosis was deﬁned as clinical features consistent with
active Cryptococcus spp infection and isolation of Cryptococcus spp
from a normally sterile site. Cryptococcal meningitis was deﬁned
as positive CSF culture for Cryptococcus spp. Pulmonary cryptococ-
cosis was deﬁned by a clinically compatible presentation with
parenchymal inﬁltrates or nodules demonstrated on chest
radiography or computed tomography for which no other cause
was apparent and Cryptococcus spp isolated from a normally sterile
site. Cryptococcaemia was deﬁned as blood cultures positive for
Cryptococcus spp. Disseminated cryptococcosis was deﬁned as
involvement of two or more non-contiguous sites according to
the criteria above.
All isolates were originally identiﬁed as C. neoformans with
the API20AUX system (bioMe´rieux), which could not distinguish
C. neoformans from C. gattii. In this study, polymerase chain
reaction–restriction fragment length polymorphism (PCR-RFLP)
was used to distinguish C. neoformans variants from C. gattii16
and to place isolates into one of eight possible molecular types:
VN I, II, III, and IV, and VG I, II, III, and IV. A multiplex PCR was
used to infer the serotype as serotyping reagents are no longer
manufactured.17 The presence of cryptococcal antigen in the
blood and CSF was determined with the use of a cryptococcal
latex agglutination system (CALAS; Meridian Diagnostic Inc.,
Cincinnati, OH, USA). Blood cultures were collected and
processed with the use of BACTEC and BacT/ALERT systems.
The collection and publication of these data was approved by
the institutional ethics review board.2.1. Statistical analysis
Descriptive statistics (means, standard deviations, median,
range, frequency counts) were used to describe the distribution of
the variables in the study population of HIV-positive and HIV-
negative patients. A Chi-square test or Fisher’s exact test was used
accordingly to evaluate differences in categorical variables. Crude
odds ratios (ORs) and 95% conﬁdence intervals (CIs) were
calculated for categorical variables. Crude ORs for continuous
variables were obtained using simple logistic regression. Stratiﬁed
analyses were used for death within 30 days after diagnosis
and CSF parameters (white blood cell count (WBC), glucose, and
protein). All tests were two-tailed and p-values less than 0.05 were
considered statistically signiﬁcant. The statistical analysis was
performed using Stata version 10 (StataCorp LP, College Station, TX,
USA).
3. Results
A total of 77 cryptococcal isolates were recovered during the
9-year study period. Medical records were available for 62 patients
with 69 positive cultures (Table 1). The mean age was 42  12 years
(range 17–76 years). Forty-nine patients (79%) were male.
The majority (81%) were infected with HIV with CD4 counts
<200 cells/mm3 (median 20 cells/mm3, range 2–140 cells/mm3).
All four patients with rheumatologic disease had systemic lupus
erythematosus (SLE). Three patients had active SLE on chronic steroid
therapy, and the remaining patient presented with neuropsychiatric
SLE, pulmonary haemorrhage, and cryptococcaemia. None were on
immunobiologicals. Five patients had no apparent underlying
medical condition, three of whom had C. gattii. The most common
symptoms were fever (79%), headache (71%), and cough (45%). On
admission 45% were febrile.
On physical examination, 12 patients (19%) had meningism.
Nine patients had cranial nerve (CN) palsies, the most common
being CN VI palsy, which was present in seven patients. Two
patients had hemiplegia. Reduced visual acuity was present in
four patients and papilloedema in three. Six patients had
cutaneous ﬁndings including folliculitis (two patients), eczema,
pyoderma gangrenosum, Kaposi sarcoma, and herpes zoster (one
patient each).
Chest radiographs were abnormal in 28 (45%) patients (Table 2).
Of the abnormal chest radiographs, nine showed coin-like
opacities, 18 showed inﬁltrates, and two had pleural effusions.
Brain imaging was performed in 61 patients. Meningeal enhance-
ment occurred in eight patients. Multiple space-occupying lesions
suggestive of cryptococcoma were present in ﬁve patients and
single space-occupying lesions in three. Sixty patients had a CSF
examination. The median opening pressure on lumbar puncture
was 23 cmH2O (range 4–50 cmH2O). The median value for the CSF
WBC was 4  106 cells/l (range 0–342  106 cells/l), glucose was
2.5 mmol/l (range 0.1 to 9 mmol/l), protein was 59 mg/dl (range
16–433 mg/dl), and the cryptococcal antigen titre was 512 (range
0–65 536). The median serum cryptococcal antigen titre was 2048
(range 0–262 144). Blood cultures obtained in our hospital were
positive for Cryptococcus spp in 29 patients, Salmonella enteritidis in
two patients, and methicillin-sensitive Staphylococcus aureus in
one patient.
Cryptococcaemia was diagnosed in 34 patients (55%). Five
patients had positive blood cultures for Cryptococcus spp at the
referring institution, prior to transfer to our hospital. Cryptococcal
meningoencephalitis was diagnosed in 55 patients (89%), respira-
tory involvement occurred in 14 (23%), and disseminated disease
in 31 (50%).
All 61 patients diagnosed ante-mortem received antifungal
treatment for cryptococcosis (Table 3). Delay in treatment was
Table 1
Demographic and clinical features of HIV-positive and HIV-negative patients with cryptococcosisa
Variables HIV-positive
(n = 50)
HIV-negative
(n = 12)
OR (95% CI) p-Value
Age, years, median (IQR) 36.5 (32–46) 49.5 (42–62.5) 0.9 (0.9–1.0) 0.006
Gender, male 42 (84) 7 (58) 3.8 (0.9–14.8) 0.05
Co-morbidities
Rheumatologic diseases 0 4 (33.3) NC 0.001
Diabetes mellitus 3 (6) 2 (16.7) 0.3 (0.04–2.2) 0.246
Liver cirrhosis 1 (2) 1 (8.3) 0.2 (0.01–3.9) 0.352
Renal diseases 0 2 (16.7) NC 0.035
Corticosteroid (>10 mg/day for 3 months) 0 5 (41.7) NC <0.001
Presenting symptoms
Duration of symptoms before presentation, days, median (IQR) 14 (7–21) 21 (5–30) 1.0 (1.0–1.01) 0.450
Fever 42 (84) 9 (75) 1.8 (0.39–7.92) 0.432
Cough 24 (48) 4 (33.3) 1.8 (0.50–6.93) 0.521
Headache 37 (74) 8 (66.7) 1.4 (0.37–5.52) 0.721
Vomiting 24 (48) 3 (25) 2.8 (0.67–11.45) 0.202
Altered mental status 7 (14) 6 (50) 0.2 (0.04–0.65) 0.013
Neck stiffness 8 (16) 3 (25) 0.6 (0.13–2.59) 0.432
Presenting signs
Respiratory 9 (18) 2 (16.7) 1.1 (0.20–5.89) 1.000
Neurologic (meningism) 11 (22) 1 (8.3) 3.1 (0.36–26.73) 0.431
Neurologic (other) 10 (20) 0 NC 0.186
Ophthalmologic 6 (12) 1 (8.3) 1.5 (0.16–13.78) 1.000
OR, odds ratio; CI, conﬁdence interval; IQR, interquartile range; NC, non-calculable.
a Data are in number (%), unless otherwise speciﬁed.
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majority (93%) received intravenous amphotericin B with half of
these patients receiving additional ﬂucytosine (45%). Fluconazole
for initial therapy was signiﬁcantly more common in HIV-negative
patients (p = 0.02). Nine patients (15%) required neurosurgical
shunt insertion. Two patients were repatriated to Thailand and one
patient each to Indonesia and Malaysia. The outcome was not
known for these four patients. For the remaining 58 patients, the
30-day mortality was 17%.
Only three patients (5%) were infected with C. gattii. All were
men with no underlying conditions (Table 4). All had disseminated
disease involving the respiratory and central nervous systems.
Molecular typing of 77 isolates showed three to be C. gattii, RFLP
type VG II, serotype B. Of the remaining 74, all were C. neoformans
var. grubii RFLP type VN I, serotype A, except for one that was RFLP
type VN II.Table 2
Laboratory and radiologic ﬁndings in HIV-positive and HIV-negative patients with cryp
Variables HIV-positive
(n = 50)
CSF parameters
Opening pressure >20 cmH2O 29 (58) 
WBC 5  106 cells/l 21 (42) 
Glucose <2.5 mmol/l 23 (46) 
Protein >0.45 g/l 26 (52) 
India ink positive 40 (80) 
Culture positive 45 (90) 
Abnormal chest radiograph 20 (40) 
Brain images (CT or MRI)
Normal 35 (70) 
Mass lesion 7 (14) 
Hydrocephalus 4 (8) 
Blood culture positive 24 (48) 
Diagnosis
CNS 46 (92) 
Pulmonary 7 (14) 
Cryptococcaemia 29 (58) 
Disseminated (more than 1 site) 25 (50) 
OR, odds ratio; CI, conﬁdence interval; CSF, cerebrospinal ﬂuid; WBC, white blood ce
calculable; CNS, central nervous system.
a Data are in number (%).4. Discussion
In this study, C. neoformans var. grubii was the most common
infecting species, affecting mainly patients with HIV. From the
identiﬁcation of the ﬁrst case of HIV infection in Singapore, which
was reported in 1985, the cumulative number of Singapore
residents diagnosed with HIV reached 5775 by the end of 2012
with the majority (93%) of new cases being male.18 Our ﬁnding that
HIV infection was the underlying condition in the majority (81%) of
cryptococcosis reﬂects the rise in HIV infection locally. In contrast,
two older studies on Singaporean patients with cryptococcal
meningitis published in 1972 (30 patients) and 1985 (25 patients)
reported few patients with pre-existing chronic disease and the
majority had no underlying immune defect.19,20
The male predominance (79%) is similar to other studies, likely
due to the gender composition of the HIV population locally,tococcosisa
HIV-negative
(n = 12)
OR (95% CI) p-Value
5 (41.7) 1.9 (0.54–6.94) 0.349
6 (50) 0.7 (0.20–2.56) 0.616
5 (41.7) 1.2 (0.33–4.27) 1.000
8 (66.7) 0.5 (0.14–2.03) 0.521
6 (50) 4.0 (1.06–15.08) 0.033
9 (75) 3.0 (0.61–14.86) 0.177
8 (66.7) 0.3 (0.09–1.26) 0.117
9 (75) 0.8 (0.18–3.28) 1.000
1 (8.3) 1.8 (0.20–16.12) 1.000
0 NC 0.578
5 (42) 1.3 (0.30–5.88) 0.693
9 (75) 3.8 (0.73–20.13) 0.125
7 (58.3) 0.1 (0.03–0.47) 0.003
5 (41.7) 1.9 (0.54–6.94) 0.349
6 (50) 1.0 (0.28–3.53) 1.000
ll count; CT, computed tomography; MRI, magnetic resonance imaging; NC, non-
Table 3
Treatments, complications, and outcomes in HIV-positive and HIV-negative patients with cryptococcosisa
Variables HIV-positive
(n = 50)
HIV-negative
(n = 12)
OR (95% CI) p-Value
Treatment
Delay to treatment, days, median (IQR) 2 (1–4) 7 (2–11) 0.8 (0.63–0.92) 0.003
Amphotericin B alone 26 (52) 3 (25) 3.2 (0.78–13.44) 0.116
Amphotericin B and 5-ﬂucytosine 23 (46) 5 (41.7) 1.2 (0.33–4.27) 0.787
Fluconazole alone 1 (2) 3 (25) 0.1 (0.006–0.66) 0.021
Amphotericin B then ﬂuconazole 42 (84) 8 (66.7) 2.6 (0.64–10.84) 0.223
Duration amphotericin B, days, median (IQR) 14 (9–17) 22 (14–33) 0.9 (0.87–0.99) 0.016
Total duration of antifungals, months, median (IQR) 17 (3–43) 15 (1–19) 1.0 (0.99–1.07) 0.414
Neurosurgery 8 (16) 1 (8.3) 2.1 (0.24–18.58) 0.675
Complications
Raised ICP needing shunts 9 (18) 0 NC 0.185
Blindness 6 (12) 0 NC 0.586
Acute renal impairment 14 (28) 7 (58.3) 0.3 (0.08–1.02) 0.086
Outcome
Length of stay, days, median (IQR) 18.5 (13–33) 31 (17.5–44.5) 0.99 (0.97–1.01) 0.192
Readmission related to Cryptococcus (n = 34) 12/27 3/7 1.1 (0.20–5.71) 0.940
Death (n = 57) 15/45 1/12 5.5 (0.65–46.69) 0.118
Death at 30 days after diagnosis (n = 58) 9/46 1/12 2.68 (0.30–127.77) 0.670
OR, odds ratio; CI, conﬁdence interval; IQR, interquartile range; ICP, intracranial pressure; NC, non-calculable.
a Data are in number (%), unless otherwise speciﬁed.
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and genetic predisposition have been suggested as contributing
factors.21 The median age of HIV-positive patients was lower
compared with HIV-negative patients, likely due to the younger
age of HIV-positive patients locally.18
The majority of HIV-positive patients (92%) had cryptococcal
meningoencephalitis, thus fever, headache, and vomiting were the
most common presenting symptoms. Altered mental state was less
common in HIV-positive patients, possibly as a result of a relatively
poor CSF inﬂammatory response.22 In contrast, neurologic deﬁcits,
in particular CN VI palsy, were present in HIV-positive patients,
likely reﬂecting raised intracranial pressure associated with
cryptococcal meningoencephalitis. HIV-positive patients were
more likely to have positive CSF India ink staining (p = 0.033),
likely due to the presence of a higher fungal burden. Despite
positive CSF cultures in the majority (87%), CSF WBC, protein, and
glucose ﬁndings were normal in 33–58%, similar to other studies.23
The diagnosis and treatment in HIV-positive patients were
signiﬁcantly earlier than in HIV-negative patients due to the earlyTable 4
Baseline characteristics, clinical presentation, laboratory ﬁndings, and treatment of thr
Characteristic Patient 1 
Age, years 47 
Sex Male 
Days of illness 30 
Presenting symptoms Fever, cough, headache, anorexia,
mental status change
Co-morbidities Nil 
Investigations
CXR Lung mass 
Brain imaging Focal brain mass 
Serum CLA, titre 262 144 
CSF CLA, titre 1024 
CSF India ink Positive 
CSF culture Positive 
Blood culture Negative 
Treatment
Delay to treatment, days 12 
Treatment AmB  28 days + 5FC  24 days
then ﬂuconazole 800 mg
LOS, days 28 
Surgery Yes 
Follow-up, years 5 
CXR, chest radiograph; CLA, cryptococcal latex agglutination; CSF, cerebrospinal ﬂuid; consideration of and testing for cryptococcosis in HIV-positive
patients. Fluconazole was more likely to be used in HIV-negative
patients for initial treatment, likely due to the predominance of
respiratory involvement compared with central nervous system
infection, which requires treatment with amphotericin B.5
Despite improvements in medical care and access to highly
active antiretroviral therapy (HAART), there was no signiﬁcant
decrease in mortality over the study time period. The overall 30-
day mortality of 16% is comparable to other studies.5 Comparing
HIV-positive to HIV-negative patients, mortality and morbidity
were not signiﬁcantly different between the two groups. This
contrasts with other studies, which have reported increased
morbidity, mortality, and surgical interventions in HIV-negative
patients.8,12,14
C. gattii, now recognized as a separate species from C.
neoformans, was ﬁrst reported in Singapore in 2002.24 Mostly
restricted to tropical and subtropical regions of Australia and
Papua New Guinea,13,14 a large outbreak in Vancouver Island and
surrounding areas within Canada, with spread into the Paciﬁcee patients with Cryptococcus gattii
Patient 2 Patient 3
39 65
Male Male
21 30
Headache, mental
status change
Fever, anorexia
Nil Nil
Lobar consolidation Lung mass
Normal Normal
8192 256
512 4096
Positive Positive
Positive Positive
Negative Negative
2 9
Fluconazole 800 mg AmB  14 days + 5FC  14 days
then ﬂuconazole 400 mg
6 37
No No
1.5 1.5
AmB, amphotericin B; 5FC, 5-ﬂucytosine; LOS, length of stay.
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this pathogen.12,25,26 In neighbouring Malaysia, C. gattii comprised
11.5% of cryptococcal infections, although notably no isolates
originated from the southern states adjacent to Singapore.27
Despite infecting hosts with normal immune status, C. gattii
behaves more aggressively than C. neoformans with higher rates of
brain mass lesion, long-term neurologic and pulmonary sequelae,
and increased need for prolonged treatment and surgery.12,14,21 In
our study, C. gattii was uncommon with only three cases (3.9%)
identiﬁed. Similar to previous studies, all patients had a normal
immune status.12,21 All patients had lung involvement, whereas
only one patient had abnormal brain imaging. Despite the small
numbers, one patient required neurosurgery and all survived.
Molecular typing techniques, such as RFLP, have become
essential tools in tracking the epidemiology of C. neoformans.16
For C. gattii, RFLP VG I, VG II, VG III, and VG IV appear to have
distinct distribution zones according to geographical and climactic
inﬂuences.28–30 Most clinical isolates from Australia and eucalyp-
tus-associated C. gattii isolates belong to RFLP VG I.31 In contrast, in
the outbreak on Vancouver Island and mainland British Columbia,
most human, veterinary, and environmental C. gattii isolates
belonged to the genotype VG II, with its two molecular subtypes
VG IIa being the predominant genotype in 90% and VG IIb in
10%.26,30,32
In our study, all C. gattii isolates were VG II. Epidemiological
studies from neighbouring countries have similarly shown the
presence of molecular type VG II in the region. In Malaysia, of eight
clinical isolates of C. gattii, half were VG I and the remaining were VG
II.27 Elsewhere in Southeast Asia, the majority of 13 clinical isolates
from Thailand were VG II, with only a single isolate of VG I.33This is in
direct contrast to Vietnam, where VG I was the predominant type
and only one of 13 isolates was found to be VG II.34
For C. neoformans var. grubii, VN I accounted for the vast
majority of isolates in our study. Similarly, all C. neoformans var.
grubii isolates were VN I in studies from Malaysia and Vietnam,27,34
and this was the predominant molecular type (94.6%) in clinical
isolates from Thailand.33 This predominance of VN I molecular type
is in concordance with other studies reported worldwide.35–37
Cryptococcosis is not a notiﬁable disease in Singapore. The data
presented in this study represent a single institution record. Our
institution supports a limited haematology and transplant service,
thus cryptococcal disease related to associated immunosuppres-
sion is lacking in this study. However, being the national referral
centre for HIV in Singapore, this study is expected to capture the
majority of HIV-related cryptococcosis. Since this was a retrospec-
tive study, not every patient had their HIV status checked. Of the
four patients who did not have HIV testing, three were diagnosed
with SLE and one had CD4 534 cells/mm3. None of the 12 patients
classiﬁed as HIV-negative had other AIDS-deﬁning illnesses before
or after the episode of cryptococcaemia. Thus, the likelihood of
undetected HIV infection was low in these patients.
This study is the ﬁrst to describe the clinical characteristics and
report on the distribution of molecular serotypes of Cryptococcus
in Singapore. In conclusion, C. neoformans var. grubii VN I is the
predominant subtype in Singapore, infecting younger, mainly
immunocompromised hosts with HIV infection. C. gattii is
uncommon, of VG II serotype, causing pulmonary manifestations
in older, immunocompetent patients.
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